D. Boral Capital Reaffirms Buy Rating for OS Therapies (NYSE:OSTX)

D. Boral Capital reiterated their buy rating on shares of OS Therapies (NYSE:OSTX) in a research report released on Tuesday morning,Benzinga reports. The firm currently has a $20.00 price objective on the stock.

Several other research analysts have also issued reports on the stock. Maxim Group lifted their price target on shares of OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, January 16th. Lake Street Capital assumed coverage on OS Therapies in a research report on Wednesday, April 2nd. They issued a “buy” rating and a $19.00 price target for the company. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, OS Therapies presently has an average rating of “Buy” and a consensus price target of $18.00.

OS Therapies Stock Performance

NYSE:OSTX opened at $1.52 on Tuesday. The company has a 50-day moving average of $1.58 and a 200-day moving average of $2.51. OS Therapies has a twelve month low of $1.12 and a twelve month high of $7.00.

Insider Activity

In other news, major shareholder Shalom Auerbach sold 50,012 shares of the company’s stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.35, for a total value of $67,516.20. Following the transaction, the insider now owns 2,756,199 shares in the company, valued at $3,720,868.65. This represents a 1.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 13.80% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC acquired a new position in shares of OS Therapies Inc (NYSE:OSTX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.